canrenone has been researched along with Liver Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P | 1 |
| Abshagen, U; L'age, M; Spörl, S | 1 |
| Branch, R; Jackson, L; Levine, D; Ramsay, L | 1 |
1 trial(s) available for canrenone and Liver Dysfunction
| Article | Year |
|---|---|
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
Topics: beta-Cyclodextrins; Biological Availability; Canrenone; Chronic Disease; Cross-Over Studies; Cyclodextrins; Diuresis; Diuretics; Female; Humans; Liver Diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome; Water-Electrolyte Balance | 1997 |
2 other study(ies) available for canrenone and Liver Dysfunction
| Article | Year |
|---|---|
Non-interaction of spironolactone medication and cortisol metabolism in man.
Topics: Canrenoic Acid; Canrenone; Drug Interactions; Humans; Hydrocortisone; Liver Diseases; Spironolactone | 1978 |
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseases; Male; Middle Aged; Pregnadienes; Serum Albumin; Spironolactone | 1977 |